Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Precirix, a Belgium-based precision radiopharmaceuticals developer spun out of Vrije Universiteit Brussel, closed an €80m ($88m) series B round today backed by V-Bio Ventures, the venture capital firm aligned with research institute VIB. The round was co-led by Inkef Capital, Jeito Capital and Forbion, and additionally included pharmaceutical firm Novo as well as Gimv, HealthCap, Pontifax Venture Capital, BioMed Partners, and all seed-stage investors, of which only Fournier-Majoie Foundation was previously identified. Precirix raised $42m in series A…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
